Intellectual Property Law 


Mika Reiner Mayer has become one of the most sought-after patent lawyers in the medical device, drug delivery, and pharmaceutical fields. In addition to preparing and prosecuting patent applications, she provides strategic patent portfolio analysis for her clients. She works extensively in performing both investor-side and company-side IP due diligence reviews. The potential investments she has overseen range in size from small seed investments to multi-billion-dollar acquisitions in the medical device, drug delivery, and pharmaceutical fields. Mika is also often relied upon to assist with some of the firm’s litigation matters involving technologies within her areas of expertise.

Mika develops IP strategies and prosecutes patent applications with a laser focus on protecting her clients’ interests and maximizing their value and commercial success. Her prosecution and due diligence engagements have helped her clients shore up their patent portfolios and raise capital to further develop their technologies. She led the IP due diligence for Gilead Sciences’ acquisition of YM Biosciences as well as the IP due diligence for Astellas Pharmaceutical’s $4 billion hostile takeover of OSI Pharmaceuticals. In all, Mika has participated in, or led, more than 400 IP due diligence reviews for some of the most sophisticated health care companies and investors in the world.

Mika is consistently called upon by top decision makers in the medical device, drug delivery, and pharmaceutical communities for her ability to translate IP risks into business risks, and provide strategic guidance and oversight in this regard. As these industries have gone global, so has her practice, with companies around the world utilizing her expertise.

She is a guest lecturer for Stanford’s Biodesign Innovation Class, a current member of the Science Accelerator Committee of the American Heart Association, and a board member of the Women in Law Empowerment Forum.